AlphaQuest LLC Increases Stake in IQVIA Holdings Inc. (NYSE:IQV)

AlphaQuest LLC raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 219.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,614 shares of the medical research company’s stock after buying an additional 4,544 shares during the quarter. AlphaQuest LLC’s holdings in IQVIA were worth $1,300,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the stock. LGT Capital Partners LTD. purchased a new stake in IQVIA during the 4th quarter valued at approximately $14,758,000. OFI Invest Asset Management purchased a new position in shares of IQVIA in the fourth quarter valued at $110,000. Haven Private LLC purchased a new position in shares of IQVIA in the fourth quarter valued at $457,000. Andra AP fonden grew its holdings in shares of IQVIA by 21.9% in the fourth quarter. Andra AP fonden now owns 63,000 shares of the medical research company’s stock valued at $12,380,000 after purchasing an additional 11,300 shares in the last quarter. Finally, Edgestream Partners L.P. purchased a new position in shares of IQVIA in the fourth quarter valued at $6,465,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on IQV. Bank of America cut their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. UBS Group cut their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. Truist Financial reissued a “buy” rating and issued a $263.00 target price (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Tuesday, March 4th. Finally, William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Stock Up 3.4 %

NYSE:IQV opened at $191.69 on Monday. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $261.72. The company has a 50-day moving average of $197.79 and a 200 day moving average of $212.63. The firm has a market cap of $33.80 billion, a PE ratio of 25.56, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.